Figures & data
Table 1. Overlapping Peptide Pool 1.
Figure 1. Peptide pool 1 induced strong T cell responses in Balb/c mice. Balb/c mice (n = 5/group) were immunized twice two weeks apart with 25 μg pGX9501 or pVAX1 (empty vector). T cell responses were analyzed on day 14 after the second injection. (A) Splenocytes were harvested, and IFN-γ ELIspot T cell responses were measured after stimulation for 20 h with overlapping peptide pools 1 or 2. (B) Antigen-specific cytotoxic lymphocyte (CTL) killing activity was evaluated by an in vivo CTL assay. Target cells at 4 × 106/ml from naïve mice were peptide-pulsed with pool 1 then labelled with a high concentration of eFlour450 in vitro. Control cells were non-peptide-pulsed cells and labelled with a low concentration of eFluor450. The cells were mixed and transferred i.v. into immunized mice. After 5 h, splenocytes were harvested, and the intensity of eFlour450 peptide labelled target cells was compared with the non-peptide-labelled negative control cells by flow cytometry. pVAX1-s-WT was made from the wild type sequence of the full-length spike protein of the SARS-CoV-2(SARS-CoV-2/WH-09/human/2020/CHN) was subcloned into the pVAX1. The sequence of the same region was optimized via SynCon technology, synthesized, and cloned into pVAX1 as the pGX9501.
![Figure 1. Peptide pool 1 induced strong T cell responses in Balb/c mice. Balb/c mice (n = 5/group) were immunized twice two weeks apart with 25 μg pGX9501 or pVAX1 (empty vector). T cell responses were analyzed on day 14 after the second injection. (A) Splenocytes were harvested, and IFN-γ ELIspot T cell responses were measured after stimulation for 20 h with overlapping peptide pools 1 or 2. (B) Antigen-specific cytotoxic lymphocyte (CTL) killing activity was evaluated by an in vivo CTL assay. Target cells at 4 × 106/ml from naïve mice were peptide-pulsed with pool 1 then labelled with a high concentration of eFlour450 in vitro. Control cells were non-peptide-pulsed cells and labelled with a low concentration of eFluor450. The cells were mixed and transferred i.v. into immunized mice. After 5 h, splenocytes were harvested, and the intensity of eFlour450 peptide labelled target cells was compared with the non-peptide-labelled negative control cells by flow cytometry. pVAX1-s-WT was made from the wild type sequence of the full-length spike protein of the SARS-CoV-2(SARS-CoV-2/WH-09/human/2020/CHN) was subcloned into the pVAX1. The sequence of the same region was optimized via SynCon technology, synthesized, and cloned into pVAX1 as the pGX9501.](/cms/asset/7c98711e-7062-466f-a56b-f07eb8bf4588/temi_a_2043727_f0001_oc.jpg)
Figure 2. IEDB prediction scores of peptides in pool 1. CTL epitope peptides were screened by integrating MHC-I binding prediction, MHC-I immunogenicity (A), and MHC-NP (B) prediction from three H-2d MHC-I alleles. The numbers on the graph are the peptide identification numbers. The different colours are corresponding to each peptide ID.
![Figure 2. IEDB prediction scores of peptides in pool 1. CTL epitope peptides were screened by integrating MHC-I binding prediction, MHC-I immunogenicity (A), and MHC-NP (B) prediction from three H-2d MHC-I alleles. The numbers on the graph are the peptide identification numbers. The different colours are corresponding to each peptide ID.](/cms/asset/adc41b1d-f733-4bf9-908b-89d890c3a7e2/temi_a_2043727_f0002_oc.jpg)
Figure 3. Peptide 2 is identified as a CD8+ CTL epitope. Balb/c mice were immunized with the pGX9501. (A) Splenocytes were obtained and used to analyze antigen-specific T-cell induction in the IFN-γ ELIspot assay using in vitro stimulation with the indicated peptides (the peptide with an MHC-I binding RANK < 2 and showing the highest TAP total score or Immunogenicity score in different alleles) was selected for the IFN-γ ELIspot assay. (B) CD4+ T cells and (C) CD8+ T cells were sorted, and specific T-cell induction of IFN-γ-secretion was assayed.
![Figure 3. Peptide 2 is identified as a CD8+ CTL epitope. Balb/c mice were immunized with the pGX9501. (A) Splenocytes were obtained and used to analyze antigen-specific T-cell induction in the IFN-γ ELIspot assay using in vitro stimulation with the indicated peptides (the peptide with an MHC-I binding RANK < 2 and showing the highest TAP total score or Immunogenicity score in different alleles) was selected for the IFN-γ ELIspot assay. (B) CD4+ T cells and (C) CD8+ T cells were sorted, and specific T-cell induction of IFN-γ-secretion was assayed.](/cms/asset/3bb0585e-a6d5-499c-b459-68fdd0799f04/temi_a_2043727_f0003_oc.jpg)
Table 2. MHC-I epitope analysis for Overlapping Peptide Pool 1.
Figure 4. Conserved Sequence & MHC-I HLA Analysis of Peptide 2. (A) The sequence of Peptide 2 was highly conserved in the 11 virus variants that have been identified as the variants of interest and the variants of concern, as published by WHO. (B) Position of Peptide 2 (yellow marked segment) in the stereoscopic structure of the spike protein. (C) The global distribution of HLA alleles. (D) Analysis of Peptide 2 by integration of MHC-I binding prediction, MHC-I immunogenicity, and MHC-NP prediction from the HLA alleles.
![Figure 4. Conserved Sequence & MHC-I HLA Analysis of Peptide 2. (A) The sequence of Peptide 2 was highly conserved in the 11 virus variants that have been identified as the variants of interest and the variants of concern, as published by WHO. (B) Position of Peptide 2 (yellow marked segment) in the stereoscopic structure of the spike protein. (C) The global distribution of HLA alleles. (D) Analysis of Peptide 2 by integration of MHC-I binding prediction, MHC-I immunogenicity, and MHC-NP prediction from the HLA alleles.](/cms/asset/2d22635e-0539-4b96-a509-3777bf667636/temi_a_2043727_f0004_oc.jpg)
Table 3. Geographic Distribution of HLA allele.
Table 4. Human MHC-I epitope analysis for peptide 2.